China's CARsgen Therapeutics raised HKD3.1bn ($400.3m) gross in an initial public offering on the Hong Kong Stock Exchange (HKEX) on 17 June, helping the chimeric antigen receptor T-cell (CAR-T) therapy developer take the top place by IPO size in the Greater China region so far this year.
A total of 94.7 million shares were priced at HKD32.80 each, the company said in a regulatory filing to the...






